In contrast to its effects on antigen-specific CTL, lenalidomide treatment (5 μm, 4 days) did not significantly (p>0.05) change the expression of intracellular XBP1 unspliced and XBP1 spliced target antigens in breast cancer (MDA-MB231, MCF7), colon cancer (LS180, SW480) and pancreatic cancer (PATU8902, Panc1) (Figure 3A). Here, XBP1 is linked to malignant colon neoplasm.